Share on StockTwits

Clovis Oncology (NASDAQ:CLVS) was the target of some unusual options trading on Friday. Investors acquired 2,308 call options on the company, Stock Ratings reports. This is an increase of 368% compared to the average volume of 493 call options.

A number of analysts have recently weighed in on CLVS shares. Analysts at Leerink Swann initiated coverage on shares of Clovis Oncology in a research note on Friday. They set an “outperform” rating and a $100.00 price target on the stock. Separately, analysts at Stifel Nicolaus upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, June 5th. They now have a $50.00 price target on the stock. Finally, analysts at Goldman Sachs cut their price target on shares of Clovis Oncology from $85.00 to $50.00 in a research note on Wednesday, June 4th. They now have a “neutral” rating on the stock. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Clovis Oncology has an average rating of “Buy” and a consensus price target of $74.13.

Shares of Clovis Oncology (NASDAQ:CLVS) traded up 10.85% during mid-day trading on Friday, hitting $40.88. The stock had a trading volume of 1,380,662 shares. Clovis Oncology has a 1-year low of $35.33 and a 1-year high of $93.33. The stock has a 50-day moving average of $38.95 and a 200-day moving average of $57.05. The company’s market cap is $1.386 billion.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.03) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.96) by $0.07. The company had revenue of $13.60 million for the quarter. During the same quarter in the prior year, the company posted ($0.72) earnings per share. Analysts expect that Clovis Oncology will post $-3.85 EPS for the current fiscal year.

Clovis Oncology, Inc (NASDAQ:CLVS) is a Development-stage Company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.